My background has been stated perviously on this forum if you would kindly look back through the postings. And your own? Why are we asking this question? I dont seem to see that it has been asked of other forum users. Is this because you disagree with my opinion?

Also, I would suggest carefully reading the JAMA meta study, "March 14, 2022
Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment
A Systematic Review and Meta-analysis" to make your own conclusions on relative vs absolute outcome using statins.

For me, I find the paper significantly discouraging on the use of statins for preventative care. Of the two cardiologist I have met with since this paper was published, both vehemently dismissed its conclusions and have stuck with their stance that statins are a proven preventative treatment. The paper was published in JAMA Internal Medicine and heavily peer reviewed, so it is not a casual statement.

Here are some of the main highlights outline directly from the summary:

"Findings Twenty-one trials were included in the analysis. Meta-analyses showed reductions in the absolute risk of 0.8% (95% CI, 0.4%-1.2%) for all-cause mortality, 1.3% (95% CI, 0.9%-1.7%) for myocardial infarction, and 0.4% (95% CI, 0.2%-0.6%) for stroke in those randomized to treatment with statins, with associated relative risk reductions of 9% (95% CI, 5%-14%), 29% (95% CI, 22%-34%), and 14% (95% CI, 5%-22%) respectively. A meta-regression exploring the potential mediating association of the magnitude of statin-induced LDL-C reduction with outcomes was inconclusive.

Conclusions and Relevance The results of this meta-analysis suggest that the absolute risk reductions of treatment with statins in terms of all-cause mortality, myocardial infarction, and stroke are modest compared with the relative risk reductions, and the presence of significant heterogeneity reduces the certainty of the evidence. A conclusive association between absolute reductions in LDL-C levels and individual clinical outcomes was not established, and these findings underscore the importance of discussing absolute risk reductions when making informed clinical decisions with individual patients."